Opko Health - Der nächste Blockbuster (Seite 253)

[Potatoehead]

Schon 3 Mille Volumen in 45 Minuten 😅

[Potatoehead]

Geht schon gut los bei unseren amerikanischen Freunden 👍

[Malecon]

OPKOs Kunde Rite Aid legt in New York los. Gut für OPKOs Labore.

COVID-19 testing sites and schedules

Rite Aid is conducting tests at its drug store at Route 155 and Central Avenue from 9 a.m. to 5 p.m. seven days a week. To make a reservation visit riteaid.com

To get a test at a county operated testing site listed below call 518-465-4771.

Whitney M. Young Jr. Health Center at 920 Lark Drive in Albany

-Monday: 8:30 a.m. to noon

-Tuesday: 1 to 4 p.m.

-Wednesday: 8:30 a.m. to noon

-Thursday: 1 to 4 p.m.

-Friday: 8:30 a.m. to noon.

Rotating Locations & Dates for the Week of May 4
Monday, May 4

-Watervliet Health Center, 1804 Second Ave. from 9 a.m. to noon.

-Equinox, 500 Central Ave 1:30 to 4 p.m.

Tuesday, May 5, 9 am – 12 pm

-Front of the County Administration Building, 1000 Seventh Ave. in Troy from 9 a.m. to noon and 1:30 to 4 p.m.

Wednesday, May 6

-Equinox, 500 Central Ave. from 9 a.m. to noon

-Watervliet Health Center from 1:30 to 4 p.m.

Thursday, May 7

-Capital South Campus, 20 Warren Street in Albany from 9 a.m. to noon

Friday, May 8

-Whitney Young Health Center, 849 Second Ave. in Lansingburgh from 9 a.m. to noon

-Watervliet Health Center from 1:30 to 4 p.m.

https://www.spotlightnews.com/news/2020/05/04/covid-19-testi…

@JohnJudge

Wie ist die Lage in den amerikanischen Foren kurz vor der Veröffentlichung der Quartalszahlen?
Ich sehe du bist lange offline, aber vielleicht kannst du noch bis morgen Abend was dazu schreiben?

[Malecon]

CONFERENCE CALL & WEBCAST INFORMATION

OPKO’s senior management will provide a business update and discuss results in greater detail in a conference call and live audio webcast at 4:30 p.m. Eastern time on Wednesday, May 6, 2020. The conference call dial-in and webcast information is as follows:

DOMESTIC DIAL-IN: [phone]
INTERNATIONAL DIAL-IN: [phone]
PASSCODE: 9095275
WEBCAST: OPKO 1Q20 Results Conference Call

For those unable to participate in the live conference call or webcast, a replay will be available beginning approximately two hours after the close of the conference call. To access the replay, dial 855-859-2056 or 404-537-3406. The replay passcode is 9095275. The replay can be accessed for a period of time on OPKO’s website at OPKO 1Q20 Results Conference Call.

https://www.opko.com/news-media/press-releases/detail/388/op…

[Malecon]

Antwort auf Beitrag Nr.: 63.559.851 von Potatoehead am 04.05.20 20:17:41

Zitat von Potatoehead: Wir stehen gleich wieder bei 2,30$. Mal schauen, ob wir wieder abprallen. War ja meistens der Fall gewesen in letzter Zeit.

Jetzt bei 2.35 USD.

Der Widerstand nach oben ist durchbrochen.

[Hastdunicht]

Antwort auf Beitrag Nr.: 63.559.851 von Potatoehead am 04.05.20 20:17:41

Wenn wir nicht abprallen, denke ich ist der Weg zu 3 $ frei.
Daumen drücken

[Potatoehead]

Wir stehen gleich wieder bei 2,30$. Mal schauen, ob wir wieder abprallen. War ja meistens der Fall gewesen in letzter Zeit.

[Malecon]

OPKO HEALTH (OPK) TO REPORT Q1 EARNINGS: WHAT'S IN STORE?

OPKO Health, Inc. OPK is scheduled to release first-quarter 2020 results on May 6, after the closing bell. In the last reported quarter, the company delivered a positive earnings surprise of 25%.

Q1 Estimates

Currently, the Zacks Consensus Estimate for first-quarter revenues is pegged at $215.9million, suggesting growth of 2.9% from the year-ago reported number. The consensus mark for earnings stands at a loss of 9 cents per share.

Key Catalysts

OPKO Health is likely to have witnessed top-line growth in the to-be-reported quarter driven by robust performance across its segments. In fact, revenues from Products are anticipated in the range of $30-$32 million (including revenues from RAYALDEE between $9.3 million and $10.5 million in the first quarter. Meanwhile, revenues from Services are anticipated between $168 million and $173 million.

OPKO Health might have benefitted from strong performance in RAYALDEE, the company’s leading renal product, in the to-be-reported quarter. Moreover, increase in total RAYALDEE prescriptions is expected to reflect on the company’s first-quarter performance.

OPKO Health, Inc. Price and EPS Surprise

In fact, the open-label Phase 2 trial for RAYALDEE in hemodialysis patients has been progressing and the initial data is anticipated in first-quarter 2020. This may get reflected in the first-quarter performance.

Further, the company’s first-quarter performance is likely to reflect the OPKO Health’s BioReference Laboratories’ sustained progress. In fact, BioReference Laboratories’ collaborations with the state of New Jersey, City of Detroit and City of Miami with respect to offering testing for COVID-19 are expected to have positively impacted the company’s performance in the to-be-reported quarter.

Additionally, per management, OPKO Health will continue to make solid investments in R&D programs throughout 2020. We expect the company to have gained from such investments in the quarter to be reported.
However, higher operating losses might weigh on the company’s overall results.

https://www.nasdaq.com/articles/opko-health-opk-to-report-q1…

Die Zahlen werden also übermorgen frühestens um 22.00 Uhr veröffentlicht. 💡 Die Börsen werden erst am Tag danach darauf reagieren.

[Malecon]

Der Kanal ist soweit intakt:

[Malecon]

Nach unten hat sich eine robuste Unterstützung im Bereich 1,90€ gebildet.

Auf dem Wochenchart kann man deutlich sehen, wie der Kurs 4mal nach oben abgeprallt ist, s. hier: